China releases 2025 NRDL and first commercial insurance drug list
In early December, the 2025 updates of China’s National Reimbursement Drug List (NRDL) were finalised with a total of 114…
Analyst Comment
Age-related macular degeneration market expected to reach $20.5bn across 7MM by 2034
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
Pharma M&A deal value up 31% YoY in 2025YTD amid return of mega-deals
Crenolanib delivers incremental benefit in FLT3/NPM1 co-mutated AML
ASH 2025: golcadomide + rituximab combo shows standout potential in R/R FL
Bipolar disorder market to reach $9.4bn across 7MM by 2034
Second round of drug prices negotiated under the IRA revealed
